)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Larimar Therapeutics
Larimar Therapeutics (LRMR) investor relations material
Larimar Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary4 Aug, 2026
Executive summary
Nomlabofusp, a therapy for Friedreich's ataxia, demonstrated a favorable long-term safety profile, sustained increases in skin frataxin (FXN) levels, and improvements in key clinical outcomes compared to natural history data, with high patient and investigator enthusiasm.
Rolling BLA submission for accelerated approval was initiated in June 2026, with the first module submitted and completion expected in the second half of 2026; FDA and EMA engagement ongoing, and FDA agreed to consider FXN as a surrogate endpoint.
Four clinical studies completed and an ongoing open-label study with over 10,000 doses administered; ten participants experienced anaphylaxis and discontinued, all recovered with standard therapy.
Dosing of the first patient in the global confirmatory Phase 3 study is expected in Q3 2026, with sites in the US, EU, UK, Canada, and Australia.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $156.3 million as of June 30, 2026, with a projected cash runway into Q3 2027.
Net loss was $32.8 million for Q2 2026 and $62.4 million for the six months ended June 30, 2026, compared to $26.2 million and $55.5 million for the same periods in 2025.
Research and development expenses for Q2 2026 were $28.0 million, up from $23.4 million in Q2 2025, mainly due to manufacturing, consulting, and BLA preparation costs.
General and administrative expenses rose to $6.4 million in Q2 2026 from $4.4 million in Q2 2025, driven by commercial readiness activities.
Stockholders' equity increased to $127.4 million as of June 30, 2026, from $78.1 million at December 31, 2025.
Outlook and guidance
Cash resources expected to fund operations into Q3 2027, but not for a full year from the financial statement issuance date; additional capital will be needed.
Preparing for a potential mid-2027 commercial launch of nomlabofusp, pending regulatory approval.
Rolling BLA submission completion expected in H2 2026; first patient dosing in Phase 3 study anticipated in Q3 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Larimar Therapeutics
- Nomlabofusp demonstrates sustained frataxin increases and clinical benefit in FA, advancing toward approval.LRMR
Corporate presentation - Nomlabofusp shows sustained FXN increases, clinical benefit, and regulatory progress.LRMRStudy update
- Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch.LRMRCorporate presentation
- Q1 2026 net loss was $29.6M; rolling BLA planned for June 2026; cash runway into Q2 2027.LRMRQ1 2026
- Promising therapy for Friedreich's ataxia advances toward FDA submission with strong clinical data.LRMRThe Citizens Life Sciences Conference 2026
- Annual meeting to vote on directors, compensation, auditor, and share increase; Board recommends approval.LRMRProxy filing
- Annual Meeting to vote on directors, compensation, auditor, and share increase, with strong governance.LRMRProxy filing
- Accelerated approval BLA is planned for Q2 2026, with a U.S. launch targeted for early 2027.LRMRStatus Update
- Nomlabofusp boosts frataxin, shows early clinical benefit, and advances toward pivotal milestones.LRMRStudy Update
Next Larimar Therapeutics earnings date
Q3 202618 Nov, 2026
Larimar Therapeutics
Next Larimar Therapeutics earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on its lead compound, CTI-1601, which is currently being developed as a potential treatment for Friedreich's ataxia, a genetic disorder that affects the nervous system and movement. Larimar leverages its proprietary intracellular delivery platform to design fusion proteins aimed at addressing other rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania, and its shares are listed on the Nasdaq.